News
DuPont, Inbiose get approval for HMO ingredient
2 Apr 2018DuPont Nutrition & Health and Inbiose have announced regulatory approval of their first human milk oligosaccharide (HMO) ingredient for infant formula in the European market.
DuPont Nutrition & Health and Inbiose have announced regulatory approval of their first human milk oligosaccharide (HMO) ingredient for infant formula in the European market. Human milk oligosaccharides, complex carbohydrates found in breast milk, are said to be an important breakthrough innovation in infant formula, developing a product with more of the health benefits associated with human milk.
There are more than 100 HMOs found in human breast milk, with 2’-fucosyllactose (2’-FL) being the most abundant. In 2016, Inbiose and DuPont Nutrition & Health (DuPont) announced a joint development and licensing agreement for the exclusive rights to produce and commercialize 2’-FL and other selected fucosylated HMOs for food applications.“After many years of critical research and significant investment, we are delighted to see the first of our range of human milk oligosaccharides becoming commercially available, thus addressing a major gap in the nutritional composition of infant formula,” said Prof. Wim Soetaert, Inbiose executive chairman. “Thanks to our successful collaboration with DuPont, our first HMO is now commercialized, with many others to come.”“The substantial equivalence dossier for 2’-FL received EU Novel Food approval in December 2017,” said Paul Tenning, regulatory affairs manager, EMEA, for DuPont, “and we are excited to be able to bring this important new ingredient for infants and children into the European market.”2’-fucosyllactose, which will be marketed by DuPont under the brand name CARE4U, is already approved for use in dietary supplements, with potential applications related to digestion and immune health.DuPont notes that, until recently, complex carbohydrates such as HMOs were not available in larger quantities from extractive sources (e.g., cow’s milk), and the few that could be chemically synthesized were prohibitively expensive. Inbiose developed a proprietary platform technology to produce specialty carbohydrates such as human milk oligosaccharides. This fermentation-based production method has now been developed to industrial levels, allowing the large-scale production of 2’-FL that is said to befully identical to the 2’-FL HMO found in human milk.“Our competency lies in the rapid development of cost-effective production methods for specialty carbohydrates,” said Joeri Beauprez, Inbiose CSO. “Through our platform technology, we will continue to excel in the production of such ingredients, making these ingredients and their health benefits available to society at large.”“We will be the leading supplier of HMOs for infant nutrition and beyond,” said Steen Lyck, global business development leader for DuPont. “Our unique experience and capabilities give DuPont the ability to leverage synergies with multiple HMOs and probiotics; 2’-FL is just the beginning.”Related news
UK High Court allows Oatly to use 'milk' on packaging
17 Jan 2024
Oatly has scored a landmark victory in the use of the word milk after the UK High Court ruled against the country’s dairy industry and permitted the term to be used on packaging.
Read moreHow brands are overcoming challenges in the plant-based sector
16 Jan 2024
Following the turbulent evolution of the plant-based market in recent years, industry players are finding innovative ways to tackle challenges such as taste, price, and nutrition and are in turn unlocking new opportunities for growth.
Read moreMapping the rise and fall and (rise, again?) of the plant-based sector
15 Jan 2024
Recent challenges in the plant-based sector such as consumer acceptance and price inflation led to dips in certain regions while others surged. Kalina Doykova, senior research analyst at Euromonitor, shares her insights into the evolution and future tr...
Read moreMeet the innovative ingredients showcased at Fi Europe’s New Product Zone
3 Jan 2024
The Food Ingredients category at Fi Europe’s New Product Zone featured 19 distinct and innovative products. From fermented delights to sustainable proteins, these ingredients are ready to make their mark in the market.
Read moreFi Europe’s New Product Zone elevates the nutrition of everyday indulgences
22 Dec 2023
At Fi Europe 2023's New Product Zone, eight health ingredients, each offering an enhanced nutritional profile of various products, were on display. These ingredients address the evolving needs of the food and beverage industry and cater to consumers se...
Read moreFi Europe’s New Product Zone explores fresh possibilities with five natural ingredients
20 Dec 2023
Fi Europe 2023's New Product Zone unveils five natural ingredients, each catering to the growing demand for clean products and embodying ethical and sustainable choices for today's conscious consumers.
Read moreExploring the path to replicating breast milk's magic in infant formula
17 Nov 2023
While breast milk is often hailed as nature's gold standard for infant nutrition, it’s not always readily available. Enter infant formula enriched with human milk oligosaccharides (HMOs), a game-changing product that seek to mirror the composition of b...
Read moreA look at the latest ‘gut health for immunity’ product launches
25 Oct 2023
From Lipton’s probiotic tea to Babybel’s snack-sized cheeses and smoothie powders, we look at some recent product launches that can benefit immune health by targeting the gut microbiome and a healthier digestive system.
Read moreAdvocacy groups condemn EU Commission for backpedalling on animal rights
3 Oct 2023
Amid rumours that the EU may abandon its plans to improve animal welfare in farming and end the use of cages, many stakeholders have condemned this possibility and urged the EU to reconsider.
Read moreMeurens Natural: Pioneering the Way in Oat-Based Nutrition
12 Sep 2023
Meurens Natural, a European trailblazer in the organic sector for more than 30 years and expert in hydrolyzed oat syrups, powders, and proteins.
Read more